Roflumilast Foam After a Year: Who Was Assessed?
SkinArticleA longer seborrheic dermatitis study reported 80.4% clear or almost clear at week 52. The denominator and study design matter when reading that percentage.
In this article
Who does the 80.4% result describe?
The 2025 study1 included 400 people using roflumilast 0.3% foam. 338 enrolled for 24 weeks; 62 were eligible and enrolled to continue to 52 weeks after a protocol amendment extended follow-up.1
At week 52, 37 of 46 assessed participants were clear or almost clear: 80.4%. It should not be read as 80.4% of all 400 participants clearing after a year.1
Was this continuous treatment against a control?
No. This manufacturer-funded, open-label study had no comparison group. Investigators instructed patients to stop when completely clear and contact the study site when dermatitis returned before restarting. Its results describe a monitored treatment course, rather than uninterrupted daily use by everyone.1
What did the controlled trial establish?
The 2024 STRATUM report compared once-daily 0.3% roflumilast foam with vehicle foam, the formulation without the active medicine, for eight weeks. Its success rates were 79.5% versus 58.0%.2
Success required a clinician rating of clear or almost clear plus at least a two-grade improvement from baseline. The comparison supports an eight-week treatment effect. It does not establish superiority over ketoconazole or another active treatment, and its success definition should be kept beside its percentage.2
Our seborrheic dermatitis treatment overview covers antifungals, shampoos and other prescription options.
What should an ongoing prescription plan include?
The current U.S. label specifies once-daily application to affected skin or scalp that is not wet. The foam is flammable during and immediately after application, must be kept out of the eyes, and is contraindicated with moderate or severe liver impairment.3
Reported adverse reactions include nausea, headache and cold-like nose or throat symptoms. Ask a pharmacist to review other medicines because some can increase exposure to roflumilast.3
Ask your prescriber what to do when the rash clears, what should trigger reassessment, and whether a return of scaling or itch should prompt a call before restarting. A study’s supervised stopping rule is not a personal prescription instruction.
The Skin Log in Skin, Head to Toe records product start dates, irritation and photographs taken in consistent light. Use those records to bring a dated account of flares and treatment to your review.
This article concerns prescription roflumilast 0.3% foam for seborrheic dermatitis. Other roflumilast products, concentrations and conditions require their own assessment.
Girl Playbook sells this book. It provides education and worksheets, not individualized medical care.
Sources
The research behind this article, in the order it’s cited. How we source our articles.
- Alexis et al., American Journal of Clinical Dermatology, 2025Long-Term Safety and Efficacy of Roflumilast Foam 0.3% in Patients with Seborrheic Dermatitis: A Phase II, Open-Label Trial of up to 52 Weeks (opens in a new tab)abcd
- Blauvelt et al., Journal of the American Academy of Dermatology, 2024Roflumilast foam 0.3% for adolescent and adult patients with seborrheic dermatitis: A randomized, double-blinded, vehicle-controlled, phase 3 trial (opens in a new tab)ab
- DailyMedZORYVE foam 0.3%: prescribing information (opens in a new tab)ab
Spotted something out of date? Tell us and we’ll check it.
